nVerses Capital LLC Makes New $60,000 Investment in Transcat, Inc. (NASDAQ:TRNS)

nVerses Capital LLC purchased a new stake in Transcat, Inc. (NASDAQ:TRNS) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 500 shares of the scientific and technical instruments company’s stock, valued at approximately $60,000.

Other institutional investors have also modified their holdings of the company. Conestoga Capital Advisors LLC boosted its stake in Transcat by 0.3% in the second quarter. Conestoga Capital Advisors LLC now owns 769,361 shares of the scientific and technical instruments company’s stock valued at $92,077,000 after acquiring an additional 2,155 shares during the period. Wasatch Advisors LP boosted its position in Transcat by 7.9% during the 1st quarter. Wasatch Advisors LP now owns 756,220 shares of the scientific and technical instruments company’s stock valued at $84,266,000 after purchasing an additional 55,121 shares during the period. Hood River Capital Management LLC boosted its position in Transcat by 21.6% during the 2nd quarter. Hood River Capital Management LLC now owns 196,838 shares of the scientific and technical instruments company’s stock valued at $23,558,000 after purchasing an additional 34,947 shares during the period. Silvercrest Asset Management Group LLC increased its position in Transcat by 4.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 58,381 shares of the scientific and technical instruments company’s stock worth $6,505,000 after buying an additional 2,542 shares during the period. Finally, Essex Investment Management Co. LLC increased its position in Transcat by 0.4% in the third quarter. Essex Investment Management Co. LLC now owns 43,444 shares of the scientific and technical instruments company’s stock worth $5,247,000 after buying an additional 171 shares during the period. Institutional investors own 98.34% of the company’s stock.

Transcat Stock Up 0.2 %

Shares of NASDAQ TRNS opened at $132.70 on Tuesday. The stock has a market cap of $1.21 billion, a P/E ratio of 78.36 and a beta of 0.67. The firm’s 50-day simple moving average is $123.11 and its 200 day simple moving average is $121.76. Transcat, Inc. has a fifty-two week low of $84.45 and a fifty-two week high of $147.12.

Transcat (NASDAQ:TRNS) last released its quarterly earnings results on Monday, July 29th. The scientific and technical instruments company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.20. The company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $69.35 million. Transcat had a net margin of 5.69% and a return on equity of 8.48%. Transcat’s revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.38 EPS. On average, sell-side analysts anticipate that Transcat, Inc. will post 2.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on TRNS shares. Craig Hallum lowered their price target on shares of Transcat from $150.00 to $138.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. HC Wainwright restated a “buy” rating and issued a $156.00 target price on shares of Transcat in a research report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $151.33.

Transcat Profile

Transcat, Inc provides calibration and laboratory instrument services in the United States, Canada, and internationally. It operates through two segments: Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.